MDM2 and neoplasm: From all 10 tested treatments, the INF_R_1288_r1 rhabdoid tumor model harboring a SMARCB1 deletion responded best to the treatment with p53-MDM2 inhibitor idasanutlin (DSP3 hit), RTK (receptor tyrosine kinase) inhibitor ponatinib (DSP3 and NGS hit) and EZH inhibitor tazemetostat (NGS hit), as these treatments substantially decreased the number of tumors with progress (PD) and improved the partial response rate.